ASCO 2025 preview – late-breakers in focus
The curtain lifts on Veritac-2, rusfertide, and another double plenary for Astra.
ELCC 2025 – BioNTech impresses in small-cell lung
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
AACR 2025 preview – a surge in dual-payload conjugates
At least 15 dual-payload ADCs will be discussed.
AACR 2025 preview – distressed biotechs seek redemption
Ikena, Senti and others look to clinical presentations at AACR.
ELCC 2025 – subQ Keytruda heads towards approval
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
ELCC 2025 – J&J takes it to Tagrisso
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
AACR 2025 preview – Roche's TIGIT postmortem
Skyscraper-01 stars at AACR's upcoming clinical trial plenary.
